*Hazard ratio 0.34 – Scientific Registry of Transplant Recipients (SRTR) report, July 2024

In the latest report released by the Scientific Registry of Transplant Recipients (SRTR.org) in July 2024, the Montefiore Einstein Heart Transplant Program is ranked first in the U.S., with the best heart transplant risk-adjusted 1-year survival, with hazard ratios of 0.32 and 0.34 for adult 1-year deceased donor graft failure and patient mortality respectively. These hazard ratios provide an estimate of how our observed results during the first year after heart transplant compare with what was expected based on modeling from transplant outcomes from all U.S. programs and considering program-specific characteristics of heart transplant candidates, recipients and donors. 

According to the SRTR, our raw, adult 1-year heart transplant graft and patient survival rates are 98.75% and 98.73%, respectively, the highest among all seven heart transplant programs in New York State which perform more than 10 adult heart transplants annually. Our pediatric 3-year heart transplant survival rate is 100%, as is our 1-year heart graft survival rate in adult heart-liver transplant recipients. Our adult 3-year heart transplant survival rates also exceed the national average. 

This extraordinary achievement is a testament to the extensive experience and expertise of our multidisciplinary team, led by world-renowned transplant doctors and surgeons, as well as our commitment to innovation, excellence and exceptional patient care across all stages of the heart transplant journey. Our elite specialists treat the most complex and high-risk cases within one of the most diverse communities in the nation, making this achievement even more remarkable. 

Giving Hope to People Who Once Had Nowhere To Turn 

As a global leader in heart transplantation, Montefiore Einstein remains at the forefront of innovation and groundbreaking research. We have pioneered innovative approaches to avoid blood transfusions, particularly for patients with religious or medical restrictions, and we are one of a few hospitals in the nation and the only destination in New York that performs bloodless heart transplants. 

We set another milestone in the history of transplantation and organ donation by performing the world’s first HIV-positive to HIV-positive heart transplant in 2022, and we have since performed the world's second and third such transplant this year, making us the only global destination for this innovative procedure. We continue to offer new hope to the sickest cardiac patients and to broaden our efforts to increase the donor pool.

We're ranked in the top 1% of all hospitals in the nation in Cardiology, Heart & Vascular Surgery according to U.S. News & World Report and are an international referral site for the most complex and high-risk cases.